Acute on Chronic Liver Failure, Multicenter Prospective Study, Platelet, Thrombelastography
Conditions
Keywords
Thrombelastography, Acute on Chronic Liver Failure, Platelet, Multicenter Prospective Study
Brief summary
Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and provides a global assessment of coagulation incorporating the cumulative effect of the interactions at various levels between plasma components and cellular component of coagulation. And through the platelet mapping, it can help provide a picture of patients' function of platelet. Based on the primary result of our derivation cohort(NCT03281278), ACLF patients with high ADP inhibition rate had high 28-day mortality.This multicenter validation cohort aims to validate the predictive role of platelet mapping in ACLF prognosis, organ failure developments and short term mortality.
Interventions
OTHERstandard treatment
standard medical treatment
Sponsors
Southwest Hospital, China
The First Hospital of Jilin University
First Affiliated Hospital of Xinjiang Medical University
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Xiangya Hospital of Central South University
Taihe Hospital
Nanfang Hospital, Southern Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* INR≥1.5 and total bilirubin≥85μmol/L
Exclusion criteria
* INR≤1.5 or total bilirubin≤85μmol/L; * those who had hepatocellular carcinoma or other types of malignancies; * obstructive biliary diseases or other disease lead to bilirubin evaluation; * those who had acute hemorrhage one week before admission * those who received platelet, cryo transfusion or plasmapheresis one week before admission * pregnancy and breastfeeding * those who received liver transplantation or kidney transplantation; * combine with other disease lead to organ failure including heart failure (NYHA IV),respiratory failure（PaO2\<60mmHg),renal insufficiency(CKD 5) and conscious disturbance (GCS\<8) * readmission; * death within 24 hours.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 28-day mortality | 28-day | death within 28-day |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 28-day progression | 28-day | progressed to EASL defined ACLF |
| 90-day mortality | 90-day | death within 90-day |
Countries
China
Outcome results
None listed